October 13, 2014
BioTissue® Hosts Educational Events on Advances in Lid Margin and Ocular Surface Treatments at the American Academy of Ophthalmology Meeting
Prominent speakers to discuss innovative therapies and provide live demos
MIAMI, Fla., October 13, 2014 – BioTissue, Inc., the industry leader in regenerative tissue therapies and ocular hygiene products for lid margin and ocular surface diseases, will host key educational events and training sessions highlighting advances in the treatment of dry eye and lid margin diseases at this year’s American Academy of Ophthalmology Meeting (AAO) taking place October 18-21, 2014 in Chicago.
BioTissue will host “From Dry Eye to Lid Margin Diseases: Promoting Quality Healing Through Evidence-Based Therapies,” which will feature a 3D training on the Reservoir Restoration Procedure for CCh Dry Eye. The event will be held on Sunday, October 19 from 5:30 p.m. – 7:30 p.m. at the Hyatt Regency. Eric Donnenfeld, MD will moderate the session which will include presentations by Brandon D. Ayres, MD, Wills Eye Institute; Neel R. Desai, MD, Eye Institute of West Florida; and Preeya K. Gupta, MD Duke Eye Center.
In addition, BioTissue will host a series of booth talks by leaders in the field for the treatment of dry eye and lid margin diseases. Presentations and live demos, including training sessions on the newly introduced Cliradex® Complete Advanced Lid Hygiene Kit, will take place throughout the show at BioTissue’s booth #3357. Topics will include: “Cutting Edge Therapies for Treating Dry Eye,” by John Sheppard, MD, “New Approaches for treating EBMD in Cataract Patients,” by Gary Wortz, MD, and “The Evolution of Cryopreserved Amniotic Membrane in Ophthalmology,” By Steve Kaufman, MD.
“Treating lid margin disease, epitheliopathy and chronic dry eye syndrome can be challenging. However there are many new cutting edge therapies, diagnostics and surgical solutions that empower us to better manage and reduce our patients’ symptoms,” said John Sheppard, MD, MMSc. “BioTissue is at the forefront of these advances bringing us innovative products that fill unmet needs in ocular surface disease: restoring vision and providing a better quality of life.”
BioTissue, Inc., a subsidiary of TissueTech, is a privately held ophthalmic biotechnology company that develops innovative wound healing and hygiene solutions for the prevention and treatment of ocular surface diseases and disorders. BioTissue provides a comprehensive line of cryopreserved amniotic membrane ocular wound healing products, including AmnioGraft®, a biologic ocular transplantation graft; AmnioGuard®, a biologic glaucoma shunt tube graft; and the PROKERA® family of biologic corneal bandage devices. These products incorporate human amniotic membrane processed with the Company’s proprietary CryoTek® method that ensures the tissue retains its full biologic activity to reduce inflammation, promote healing, minimize corneal scarring and pain, and inhibit the angiogenic process. BioTissue also developed and markets the Cliradex® line of products, a natural lid, lash and facial cleanser with 4-Terpineol, the active component of tea tree oil (TTO), for the management of symptoms in ocular diseases such as blepharitis, demodex, and rosacea. For more information, visit www.biotissue.com